Clinical trial • Phase I • Oncology

OMTX705 for Advanced solid tumors | Carcinoma | Leiomyosarcoma | Sarcoma

Phase I trial of OMTX705 for Advanced solid tumors | Carcinoma | Leiomyosarcoma | Sarcoma. adaptive. 113 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Advanced solid tumors | Carcinoma | Leiomyosarcoma | Sarcoma
Trial Stage
Phase I
Drug Modality
ADC | Monoclonal antibody | Small molecule

Key dates

Initial CTIS Submission Date
19-06-2024
First CTIS Authorization Date
01-07-2024

Trial design

adaptive Phase I trial across 11 sites in Spain.

Adaptive
Yes
Single Multiple Or Escalation Dose Combined
Yes
Target Sample Size
113

Recruitment

Planned Sample Size
113
Recruitment Window Months
68

Geography

Total Number Of Sites
11
Total Number Of Participants
113

Spain

Earliest CTIS Part Ii Submission Date
28-06-2024
Latest Decision Or Authorization Date
22-04-2026
Processing Time Days
663
Number Of Sites
11
Number Of Participants
113

Sites

Site Name
Hospital Universitario 12 De Octubre
Department Name
Oncology
Principal Investigator Name
Luis Paz-Ares Rodríguez
Principal Investigator Email
lpazares@hotmail.com
Contact Person Name
Luis Paz-Ares Rodríguez
Contact Person Email
lpazares@hotmail.com
Site Name
Hospital General Universitario Gregorio Maranon
Department Name
Oncology
Principal Investigator Name
Rosa Álvarez Álvarez
Principal Investigator Email
rosa.alvarez@gmail.com
Contact Person Name
Rosa Álvarez Álvarez
Contact Person Email
rosa.alvarez@gmail.com
Site Name
Hospital Universitario Ramon Y Cajal
Department Name
Oncology
Principal Investigator Name
Justo Ortega Anselmi
Principal Investigator Email
justo.ortega@salud.madrid.org
Contact Person Name
Justo Ortega Anselmi
Contact Person Email
justo.ortega@salud.madrid.org
Site Name
MD Anderson Cancer Center
Department Name
Oncology
Principal Investigator Name
Ricardo Cubedo Cervera
Principal Investigator Email
rcubedo@mdanderson.es
Contact Person Name
Ricardo Cubedo Cervera
Contact Person Email
rcubedo@mdanderson.es
Site Name
Fundacion Onkologikoa Fundazioa
Department Name
Oncology
Principal Investigator Name
Ander Urruticoechea
Principal Investigator Email
anderu@onkologikoa.org
Contact Person Name
Ander Urruticoechea
Contact Person Email
anderu@onkologikoa.org
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Oncology
Principal Investigator Name
Irene Carrasco García
Principal Investigator Email
irenecg1990@gmail.com
Contact Person Name
Irene Carrasco García
Contact Person Email
irenecg1990@gmail.com
Site Name
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Department Name
Oncology
Principal Investigator Name
Claudia Valverde Morales
Principal Investigator Email
cvalverde@vhio.net
Contact Person Name
Claudia Valverde Morales
Contact Person Email
cvalverde@vhio.net
Site Name
Clinica Universidad De Navarra
Department Name
Oncology
Principal Investigator Name
Mariano Ponz Sarvisé
Principal Investigator Email
mponz@unav.es
Contact Person Name
Mariano Ponz Sarvisé
Contact Person Email
mponz@unav.es
Site Name
Institut Catala D'oncologia
Department Name
Medical Oncology
Principal Investigator Name
Marta Gil Martín
Principal Investigator Email
mgilmartin@iconcologia.net
Contact Person Name
Marta Gil Martín
Contact Person Email
mgilmartin@iconcologia.net
Site Name
Hospital Universitario Donostia
Department Name
Medical Oncology
Principal Investigator Name
Ana Paisán Ruiz
Principal Investigator Email
ana.paisanruiz@osakidetza.eus
Contact Person Name
Ana Paisán Ruiz
Contact Person Email
ana.paisanruiz@osakidetza.eus
Site Name
Complexo Hospitalario Universitario De Santiago
Department Name
Oncology
Principal Investigator Name
Rafael López López
Principal Investigator Email
rafael.lopez.lopez@sergas.es
Contact Person Name
Rafael López López
Contact Person Email
rafael.lopez.lopez@sergas.es

Sponsor

Primary sponsor

Full Name
Oncomatryx Biopharma S.L.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
OMTX705
Active Substance
OMTX705
Modality
ADC
Investigational Product Name
Pembrolizumab
Active Substance
Pembrolizumab
Modality
Monoclonal antibody
Investigational Product Name
Pazopanib
Active Substance
Pazopanib
Modality
Small molecule
Combination Treatment
Yes

Related trials

Other published trials that may interest you.